BiotechTube

KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Sclerosis, Primary Progressive

Conditions

Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS

Trial Timeline

Sep 20, 2024 → Jan 1, 2029

NCT ID
NCT06384976

About KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB

KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB is a phase 2 stage product being developed by Kyverna Therapeutics for Multiple Sclerosis, Primary Progressive. The current trial status is active. This product is registered under clinical trial identifier NCT06384976. Target conditions include Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06384976Phase 2Active

Competing Products

20 competing products in Multiple Sclerosis, Primary Progressive

See all competitors
ProductCompanyStageHype Score
Placebo + PirtobrutinibEli LillyPhase 2
52
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
NEX-20ANanexa ABPhase 1
28
agenT-797MiNK TherapeuticsPhase 1
25
Duloxetine Hydrochloride (HCI) + PlaceboEli LillyPhase 3
77
TemferonGenenta SciencePhase 1/2
33
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
77
CS-0777 tablets + CS-0777 tablets + CS-0777 tabletsDaiichi SankyoPhase 1
33
ASP7487, Velcade, DexamethasoneAstellas PharmaPhase 1/2
41
PHE885NovartisPhase 2
52
Mirabegron + PlaceboAstellas PharmaApproved
85
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
85
Denileukin Diftitox (Ontak)EisaiPhase 1
33
PalonosetronEisaiPhase 2
52
BIW-8962Kyowa KirinPhase 1
33
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)Kyowa KirinPhase 2
52
KW-2478 + BortezomibKyowa KirinPhase 1/2
41
ONO-2808 + PlaceboOno PharmaceuticalPhase 2
52
KW-2478Kyowa KirinPhase 1
33

Other Products from Kyverna Therapeutics

Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101Phase 2/3
57
Standard lymphodepletion regimenPhase 2
44
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapyPhase 1/2
33
KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimenPhase 1/2
33
KYV-101 + Standard lymphodepletion regimenPhase 1/2
33